372 related articles for article (PubMed ID: 32934314)
1. FGF18-FGFR2 signaling triggers the activation of c-Jun-YAP1 axis to promote carcinogenesis in a subgroup of gastric cancer patients and indicates translational potential.
Zhang J; Wong CC; Leung KT; Wu F; Zhou Y; Tong JHM; Chan RCK; Li H; Wang Y; Yan H; Liu L; Wu WKK; Chan MWY; Cheng ASL; Yu J; Wong N; Lo KW; To KF; Kang W
Oncogene; 2020 Oct; 39(43):6647-6663. PubMed ID: 32934314
[TBL] [Abstract][Full Text] [Related]
2. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
[TBL] [Abstract][Full Text] [Related]
3. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
[TBL] [Abstract][Full Text] [Related]
4. Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer.
Chang J; Wang S; Zhang Z; Liu X; Wu Z; Geng R; Ge X; Dai C; Liu R; Zhang Q; Li W; Li J
Oncotarget; 2015 Feb; 6(4):2009-22. PubMed ID: 25576915
[TBL] [Abstract][Full Text] [Related]
5. AMOTL1 enhances YAP1 stability and promotes YAP1-driven gastric oncogenesis.
Zhou Y; Zhang J; Li H; Huang T; Wong CC; Wu F; Wu M; Weng N; Liu L; Cheng ASL; Yu J; Wong N; Lo KW; Tang PMK; Kang W; To KF
Oncogene; 2020 May; 39(22):4375-4389. PubMed ID: 32313226
[TBL] [Abstract][Full Text] [Related]
6. Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells.
Kwak Y; Cho H; Hur W; Sim T
Mol Cancer Ther; 2015 Oct; 14(10):2292-302. PubMed ID: 26294741
[TBL] [Abstract][Full Text] [Related]
7. miR-375 is involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in gastric carcinogenesis.
Kang W; Huang T; Zhou Y; Zhang J; Lung RWM; Tong JHM; Chan AWH; Zhang B; Wong CC; Wu F; Dong Y; Wang S; Yang W; Pan Y; Chak WP; Cheung AHK; Pang JCS; Yu J; Cheng ASL; To KF
Cell Death Dis; 2018 Jan; 9(2):92. PubMed ID: 29367737
[TBL] [Abstract][Full Text] [Related]
8. The transcription factor RUNX2 fuels YAP1 signaling and gastric cancer tumorigenesis.
Guo Z; Zhou K; Wang Q; Huang Y; Ji J; Peng Y; Zhang X; Zheng T; Zhang Z; Chong D; Yang Z
Cancer Sci; 2021 Sep; 112(9):3533-3544. PubMed ID: 34160112
[TBL] [Abstract][Full Text] [Related]
9. Verteporfin targeting YAP1/TAZ-TEAD transcriptional activity inhibits the tumorigenic properties of gastric cancer stem cells.
Giraud J; Molina-Castro S; Seeneevassen L; Sifré E; Izotte J; Tiffon C; Staedel C; Boeuf H; Fernandez S; Barthelemy P; Megraud F; Lehours P; Dubus P; Varon C
Int J Cancer; 2020 Apr; 146(8):2255-2267. PubMed ID: 31489619
[TBL] [Abstract][Full Text] [Related]
10. FGFR2 Promotes Gastric Cancer Progression by Inhibiting the Expression of Thrombospondin4 via PI3K-Akt-Mtor Pathway.
Huang T; Liu D; Wang Y; Li P; Sun L; Xiong H; Dai Y; Zou M; Yuan X; Qiu H
Cell Physiol Biochem; 2018; 50(4):1332-1345. PubMed ID: 30355943
[TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA LINC00649 regulates YES-associated protein 1 (YAP1)/Hippo pathway to accelerate gastric cancer (GC) progression via sequestering miR-16-5p.
Wang H; Di X; Bi Y; Sun S; Wang T
Bioengineered; 2021 Dec; 12(1):1791-1802. PubMed ID: 33975517
[TBL] [Abstract][Full Text] [Related]
12. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.
Liu YJ; Shen D; Yin X; Gavine P; Zhang T; Su X; Zhan P; Xu Y; Lv J; Qian J; Liu C; Sun Y; Qian Z; Zhang J; Gu Y; Ni X
Br J Cancer; 2014 Mar; 110(5):1169-78. PubMed ID: 24518603
[TBL] [Abstract][Full Text] [Related]
13. Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis.
Kang W; Tong JH; Chan AW; Lee TL; Lung RW; Leung PP; So KK; Wu K; Fan D; Yu J; Sung JJ; To KF
Clin Cancer Res; 2011 Apr; 17(8):2130-9. PubMed ID: 21346147
[TBL] [Abstract][Full Text] [Related]
14. YAP1 enhances cell proliferation, migration, and invasion of gastric cancer in vitro and in vivo.
Sun D; Li X; He Y; Li W; Wang Y; Wang H; Jiang S; Xin Y
Oncotarget; 2016 Dec; 7(49):81062-81076. PubMed ID: 27835600
[TBL] [Abstract][Full Text] [Related]
15. Circular RNA YAP1 inhibits the proliferation and invasion of gastric cancer cells by regulating the miR-367-5p/p27
Liu H; Liu Y; Bian Z; Zhang J; Zhang R; Chen X; Huang Y; Wang Y; Zhu J
Mol Cancer; 2018 Oct; 17(1):151. PubMed ID: 30336780
[TBL] [Abstract][Full Text] [Related]
16. High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.
Pearson A; Smyth E; Babina IS; Herrera-Abreu MT; Tarazona N; Peckitt C; Kilgour E; Smith NR; Geh C; Rooney C; Cutts R; Campbell J; Ning J; Fenwick K; Swain A; Brown G; Chua S; Thomas A; Johnston SRD; Ajaz M; Sumpter K; Gillbanks A; Watkins D; Chau I; Popat S; Cunningham D; Turner NC
Cancer Discov; 2016 Aug; 6(8):838-851. PubMed ID: 27179038
[TBL] [Abstract][Full Text] [Related]
17. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification.
Van Cutsem E; Bang YJ; Mansoor W; Petty RD; Chao Y; Cunningham D; Ferry DR; Smith NR; Frewer P; Ratnayake J; Stockman PK; Kilgour E; Landers D
Ann Oncol; 2017 Jun; 28(6):1316-1324. PubMed ID: 29177434
[TBL] [Abstract][Full Text] [Related]
18. FGF18, a prominent player in FGF signaling, promotes gastric tumorigenesis through autocrine manner and is negatively regulated by miR-590-5p.
Zhang J; Zhou Y; Huang T; Wu F; Pan Y; Dong Y; Wang Y; Chan AKY; Liu L; Kwan JSH; Cheung AHK; Wong CC; Lo AKF; Cheng ASL; Yu J; Lo KW; Kang W; To KF
Oncogene; 2019 Jan; 38(1):33-46. PubMed ID: 30082912
[TBL] [Abstract][Full Text] [Related]
19. A novel YAP1/SLC35B4 regulatory axis contributes to proliferation and progression of gastric carcinoma.
Liu J; Zhao X; Wang K; Zhang X; Yu Y; Lv Y; Zhang S; Zhang L; Guo Y; Li Y; Yang A; Zhang R; Li J
Cell Death Dis; 2019 Jun; 10(6):452. PubMed ID: 31175271
[TBL] [Abstract][Full Text] [Related]
20. Acquired Resistance to FGFR Inhibitor in Diffuse-Type Gastric Cancer through an AKT-Independent PKC-Mediated Phosphorylation of GSK3β.
Lau WM; Teng E; Huang KK; Tan JW; Das K; Zang Z; Chia T; Teh M; Kono K; Yong WP; Shabbir A; Tay A; Phua NS; Tan P; Chan SL; So JBY
Mol Cancer Ther; 2018 Jan; 17(1):232-242. PubMed ID: 28978722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
